Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Venous Thrombosis 2Venous Thromboembolism 2Lung Neoplasms 2Thromboembolism 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Liver Diseases 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Dalteparin 4Saline Solution 3Gemcitabine 3Enoxaparin 3Warfarin 2Tinzaparin 2Heparin, Low-Molecular-Weight 2Fondaparinux 2Aspirin 2130-nm albumin-bound paclitaxel 2palbociclib 1isoquercitrin 1enoxaparin sodium 1edoxaban 1apixaban 1alvocidib 1Tranexamic Acid 1Sodium Chloride 1Sodium Bicarbonate 1Rivaroxaban 1Pentetic Acid 1PEGPH20 1Nadroparin 1Minocycline 1Ketoconazole 1Heparin 1Fluorodeoxyglucose F18 1Fluoridation 1Estramustine 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thromboembolism × Nadroparin × Clear all
NCT00951574 2012-02-01

Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)

Italfarmaco

Phase 3 Completed
1,166 enrolled

Neoplasm Metastasis, Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡